Middle East and Africa Skin Cancer Diagnostics Market Share and Forecast by 2028

Middle East and Africa Skin Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Melanoma and Non-Melanoma) and Screening Type (Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy)

Historic Data: 2019-2020 | Base Year: 2021 | Forecast Period: 2022-2028
  • Status : Published
  • Report Code : TIPRE00029076
  • Category : Life Sciences
  • No. of Pages : 88
  • Available Report Formats : pdf-format excel-format
  • Last update date : May 23, 2022
Middle East and Africa Skin Cancer Diagnostics Market Share and Forecast by 2028
Report Date: May 23, 2022   |   Report Code: TIPRE00029076 Email: sales@theinsightpartners.com

2021 Market Size

US$ 160.5 Mn

Base year value

2028 Forecast

US$ 214.3 Mn

Projected by 2028

CAGR 2022-2028

4.2 %

Growth rate

Addressable Market

US$ 1,328.96 Mn

(2022-2028)

The Middle East & Africa skin cancer diagnostics market is expected to reach US$ 214.3 million by 2028 from US$ 160.5 million in 2021; it is estimated to grow at a CAGR of 4.2% from 2021 to 2028.

Technologically advanced dermatoscopes aid in better visualizing skin cancers and has improved diagnostics sensitivity by 10–30%. Similarly, developments in AI technology enabled its application in the early detection of skin cancer. In February 2022, researchers at Fraunhofer Center for Assistive Information and Communication Solutions (AICOS) in Porto and Lisbon announced their Derm.AI software that offers a smooth primary assessment of skin lesions on the skin surface that look potentially dangerous. It combines the photos of skin lesions taken from smartphones with image analysis software and AI. The software is likely to help dermatologists to access and analyze cases and risks of skin cancer. At present, the researchers of the Derm.AI solution aim to improve the existing teledermatology processes in the Portuguese National Health System. They are also working on developing solutions for analyzing the results from mobile apps, further enhancing the deep-learning model of Derm.AI. The software was developed in partnership with shared services of the Ministry of Health and clinical partners, namely IPO Coimbra, CHUP, and ULS Guarda.

With the new features and technologies, vendors attract new customers and expand their footprints in emerging markets. This factor is driving the growth of the Middle East & Africa skin cancer diagnostics market at a promising CAGR.

Middle East & Africa Skin Cancer Diagnostics Market Revenue And Forecast To 2028 (US$ Million)

Middle East & Africa Skin Cancer Diagnostics Market Revenue And Forecast To 2028 (US$ Million)
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

The skin cancer diagnostics market is segmented into type and screening type. Based on type, the market is segmented into melanoma and non-melanoma. Based on screening type, the market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. Based on country, the market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa.

AMLo Biosciences Limited; DermLite LLC; bioMerieux SA; Hoffmann-La Roche Ltd.; and Michelson Diagnostics Ltd. are among the leading companies in the Middle East & Africa skin cancer diagnostics market.      

 

Middle East and Africa Skin Cancer Diagnostics Report Scope

Report Attribute Details
Market size in 2021 US$ 160.5 Million
Market Size by 2028 US$ 214.3 Million
CAGR (2021 - 2028) 4.2%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Type
  • Melanoma and Non-Melanoma
By Screening Type
  • Blood Tests
  • Dermatoscopy
  • Imaging Tests
  • Lymph Node Biopsy
  • Skin Biopsy
Regions and Countries Covered Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • AMLo Biosciences Limited
  • DermLite LLC
  • F. HOFFMANN-LA ROCHE LTD
  • bioMerieux SA
  • Michelson Diagnostics Ltd.
Trupti Wadekar
Assistant Manager,
Market Research & Consulting

Trupti is a senior consultant with over 10 years of experience in the Healthcare sector, specializing in pharmaceuticals, biotechnology, and life-sciences markets. She holds a Bachelor’s degree in Biotechnology and an MBA with dual specialization in Marketing and Pharmaceuticals & Biotechnology, combining a strong scientific foundation with a strategic and commercial perspective. Her professional experience encompasses market research, competitive intelligence, strategic advisory, and business development, supporting clients across diverse and evolving healthcare markets.

She has worked extensively on market sizing and assessment, growth strategy, market expansion, and strategic decision-making initiatives, helping clients identify opportunities and address complex business challenges. Trupti brings strong expertise in client engagement, stakeholder management, team leadership, and translating research findings into actionable business insights. Her ability to connect scientific understanding with market dynamics and commercial strategy enables her to deliver practical, high-impact solutions aligned with client objectives.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA